



CLAIMS


1. A compound represented by general formula (I):



wherein:



represents



Ring 1 represents a 3- to 15-membered ring;

R^1 represents a halogen, an oxo group, a hydroxyl group, a cyano group, NR^4R^5 , a C1-4 alkyl group, or a C1-4 alkoxy group, said C1-4 alkyl group or C1-4 alkoxy group may be substituted with a halogen;

R^4 and R^5 each independently represent a hydrogen atom, a C1-4 alkyl group, or a C1-4 acyl group;

p represents an integer of 0 to 7;

R^3 represents a C1-4 alkyl group, a C2-4 alkenyl group, a C2-4 alkynyl group, a (C3-6 cycloalkyl)-(CH₂)_r - group, or a (3- to 6-membered saturated heterocycle)-(CH₂)_s - group, said R^3 may be substituted with a halogen;

r represents an integer of 0 to 4;

s represents an integer of 0 to 4;

Ring 2 represents a 3- to 15-membered ring;

R^2 represents a halogen, an oxo group, a hydroxyl group, a cyano group, $C(O)R^6$, SO_2R^7 , a C1-4 alkyl group, or a C1-4 alkoxy group,

said C1-4 alkyl group or C1-4 alkoxy group may be substituted with a substituent selected from the group consisting of a halogen, a hydroxyl group, a cyano group, $C(O)R^8$, NR^9R^{10} , and SO_2R^{11} ;

R^6 represents a hydroxyl group, a C1-4 alkyl group, a C1-4 alkoxy group, or $NR^{12}R^{13}$;

R^7 and R^{11} each independently represent a hydroxyl group, a C1-4 alkyl group, or a C3-6 cycloalkyl group, said C1-4 alkyl group may be substituted with a halogen or CO_2R^{14} ;

R^8 represents a hydroxyl group, a C1-4 alkoxy group, or $NR^{15}R^{16}$;

R^9 , R^{10} , R^{12} , and R^{13} each independently represent a hydrogen atom, a C1-4 acyl group, or a C1-4 alkyl group that may be substituted with $NR^{15}R^{16}$;

R^9 and R^{10} , as well as R^{12} and R^{13} , taken together with the nitrogen atom to which they are attached, may form a 5- to 6-membered saturated cyclic amine;

R^{14} represents a hydrogen atom or a C1-4 alkyl group;

R^{15} or R^{16} each independently represents a hydrogen atom, a C1-4 alkyl, or a C1-4 acyl group;

R^{15} and R^{16} , taken together with the nitrogen atom to which they are attached, may form a 5- to 6-membered saturated cyclic amine;


q represents an integer of 0 to 7;

provided that when p and q each represent an integer of 2 or more, R^1 and R^2 each independently may be the same or different;

a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these.


2. The compound according to claim 1, wherein q is an integer of 1 or more.
3. The compound according to claim 1 or 2, which is represented by general

formula (I-a):



wherein, all symbols represent the same meanings as symbols set forth in claim 1.

4. The compound according to claim 1 or 2, which is represented by general formula (I-b):




wherein, all symbols represent the same meanings as symbols set forth in claim 1.

5. The compound according to any one of claims 1, 2 and 4, wherein R^3 is a C3-4 branched alkyl group that may be substituted with a halogen.

6. The compound according to any one of claims 1, 2, 4, and 5, wherein Ring 2 is a benzene ring, and when q represents an integer of 1 or more, at least one R^2 is a halogen.

7. The compound according to any one of claims 1, 2, 4, and 5, wherein Ring 2 is a 5- to 6-membered monocyclic aromatic heterocycle.

8. The compound according to claim 1, which is represented by general formula (I-c):



wherein, all symbols represent the same meanings as symbols set forth in claim 1.

9. A compound, which is:

(1)

N⁶-(1,3-dimethyl-1H-pyrazol-4-yl)-3-(1H-indol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine;

(2)

N⁶-(1,3-dimethyl-1H-pyrazol-4-yl)-3-(7-fluoro-1H-indazol-4-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine;

(3)

3-(7-chloro-1H-indazol-4-yl)-N⁶-[2-fluoro-4-(methylsulfonyl)phenyl]-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine;

(4)

N⁶-[2-fluoro-4-(methylsulfonyl)phenyl]-3-(1H-indazol-4-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine;

(5)

3-(7-fluoro-1H-indazol-4-yl)-N⁶-[2-fluoro-4-(methylsulfonyl)phenyl]-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine; or

(6)

4-(4-amino-2-{{2-fluoro-4-(methylsulfonyl)phenyl}amino}-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-1H-indazole-7-carbonitrile.

10. A compound, which is:

(1)

N⁶-(1,3-dimethyl-1H-pyrazol-4-yl)-3-(1H-indol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine;

(2)

N⁶-(1,3-dimethyl-1H-pyrazol-4-yl)-3-(7-fluoro-1H-indazol-4-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine;

(3)

3-(7-chloro-1H-indazol-4-yl)-N⁶-[2-fluoro-4-(methylsulfonyl)phenyl]-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine;

(4)

N⁶-[2-fluoro-4-(methylsulfonyl)phenyl]-3-(1H-indazol-4-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine;

(5)

3-(7-fluoro-1H-indazol-4-yl)-N⁶-[2-fluoro-4-(methylsulfonyl)phenyl]-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine; or

(6)

4-(4-amino-2-{[2-fluoro-4-(methylsulfonyl)phenyl]amino}-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-1H-indazole-7-carbonitrile;

a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these.

11. A pharmaceutical composition comprising the compound represented by general formula (I) according to claim 1, a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these as an active ingredient.

12. The composition according to claim 11, which is a Brk inhibitor.

13. The composition according to claim 11, which is an agent for use in preventing and/or treating cancer.

14. The composition according to claim 13, wherein the cancer is breast cancer,

ovarian cancer, large bowel cancer, lung cancer, prostate cancer, head and neck cancer, lymphoma, brain tumor, glioma, pituitary adenoma, uveal malignant melanoma, meningioma, thymoma, mesothelioma, esophageal cancer, gastric cancer, duodenal cancer, hepatocellular cancer, bile duct cancer, gallbladder cancer, pancreatic cancer, renal cell cancer, renal pelvis-ureteral cancer, bladder cancer, penile cancer, testicular cancer, uterine cancer, vaginal cancer, vulvar cancer, skin cancer, malignant bone tumor, soft tissue sarcoma, chondrosarcoma, leukemia, myelodysplastic syndrome, and multiple myeloma.

15. A medicament comprising the compound represented by general formula (I) according to claim 1, a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these in combination with at least one kind selected from an alkylating agent, an antimetabolite, an anticancer antibiotic, a plant-derived preparation, a hormone preparation, a platinum compound, a topoisomerase inhibitor, a kinase inhibitor, an anti-CD20 antibody, an anti-HER2 antibody, an anti-EGFR antibody, and an anti-VEGF antibody.

16. The compound represented by general formula (I) according to claim 1, a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these for use in preventing and/or treating cancer.

17. Use of the compound represented by general formula (I) according to claim 1, a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these for the manufacture of an agent for preventing and/or treating cancer.

18. N^6 -(1,3-dimethyl-1H-pyrazol-4-yl)-3-(1H-indol-5-yl)-1-isopropyl-1H-pyrazolo [3,4-d]pyrimidine-4,6-diamine.

19. N^6 -(1,3-dimethyl-1H-pyrazol-4-yl)-3-(1H-indol-5-yl)-1-isopropyl-1H-pyrazolo [3,4-d]pyrimidine-4,6-diamine, a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these.